Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Director comp.
Credit agrmnt [a]
Acq. announced
Consulting agrmnt
Quarterly results
Horizon Therapeutics Public Ltd Co (HZNP) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Investor presentation, Quarterly results
Docs: "Horizon Therapeutics plc Reports Second-Quarter 2023 Financial Results",
"Investor Presentation of Horizon Therapeutics plc"
08/03/2022 8-K Quarterly results
Docs: "Horizon Therapeutics plc Reports Second-Quarter 2022 Financial Results and Revises Full-Year 2022 Net Sales and Adjusted EBITDA Guidance"
05/04/2022 8-K Quarterly results
03/01/2022 8-K Quarterly results
11/03/2021 8-K Quarterly results
Docs: "Horizon Therapeutics plc Reports Record Third-Quarter 2021 Financial Results; Increasing Full-Year 2021 Net Sales and Adjusted EBITDA Guidance"
08/04/2021 8-K Quarterly results
Docs: "Horizon Therapeutics plc Reports Record Second-Quarter 2021 Financial Results; Increasing Full-Year 2021 Net Sales and Adjusted EBITDA Guidance"
05/05/2021 8-K Quarterly results
02/24/2021 8-K Quarterly results
11/02/2020 8-K Quarterly results
Docs: "Horizon Therapeutics plc Reports Record Third-Quarter 2020 Results"
08/05/2020 8-K Quarterly results
05/06/2020 8-K Quarterly results
02/26/2020 8-K Quarterly results
11/06/2019 8-K Quarterly results
08/07/2019 8-K Quarterly results
05/08/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 8, 2019 Horizon Therapeutics Public Limited Company Ireland 001-35238 Not Applicable Connaught House, 1st Floor, 1 Burlington Road, Dublin 4, D04 C5Y6, Ireland Registrant's telephone number, including area code: 011-353-1-772-2100 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14...",
"Horizon Therapeutics plc Reports Strong First-Quarter 2019 Results; Increases Full-Year 2019 Net Sales and Adjusted EBITDA Guidance"
02/27/2019 8-K Quarterly results
11/07/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 7, 2018 Horizon Pharma Public Limited Company Ireland 001-35238 Not Applicable Connaught House, 1st Floor, 1 Burlington Road, Dublin 4, D04 C5Y6, Ireland Registrant's telephone number, including area code: 011-353-1-772-2100 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d...",
"Horizon Pharma plc Reports Third-Quarter Net Sales Growth of 20 Percent Driven by Orphan and Rheumatology Net Sales Growth of 25 Percent; Increases Full-Year 2018 Adjusted EBITDA Guidance"
08/08/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : August 8, 2018 Horizon Pharma Public Limited Company Ireland 001-35238 Not Applicable Connaught House, 1st Floor, 1 Burlington Road, Dublin 4, D04 C5Y6, Ireland Registrant's telephone number, including area code: 011-353-1-772-2100 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2...",
"Horizon Pharma plc Reports Record Quarterly Net Sales for Orphan and Rheumatology Segment; Increases Full-Year 2018 Adjusted EBITDA Guidance; Implements New Company Operating Structure to Enhance Focus on Rare Diseases"
05/09/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 9, 2018 Horizon Pharma Public Limited Company Ireland 001-35238 Not Applicable Connaught House, 1st Floor, 1 Burlington Road, Dublin 4, D04 C5Y6, Ireland Registrant's telephone number, including area code: 011-353-1-772-2100 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 un...",
"Horizon Pharma plc Reports Strong First-Quarter 2018 Orphan and Rheumatology Net Sales Growth; Increases Full-Year 2018 Guidance and Announces New Company Operating Structure to Enhance Focus on Rare Diseases"
02/28/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Horizon Pharma plc Announces Fourth-Quarter and Full-Year 2017 Results"
11/06/2017 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 6, 2017 Horizon Pharma Public Limited Company Ireland 001-35238 Not Applicable Connaught House, 1st Floor, 1 Burlington Road, Dublin 4, D04 C5Y6, Ireland Registrant's telephone number, including area code: 011-353-1-772-2100 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d...",
"Horizon Pharma plc Announces Third-Quarter and Year-to-Date 2017 Results"
08/07/2017 8-K Quarterly results
Docs: "FORM 8-K",
"Horizon Pharma plc Announces Second-Quarter and Year-to-Date 2017 Results and Increases Full-Year 2017 Net Sales and Adjusted EBITDA Guidance"
05/08/2017 8-K Form 8-K - Current report
02/27/2017 8-K Form 8-K - Current report
11/07/2016 8-K Quarterly results
Docs: "Horizon Pharma plc Announces Third-Quarter 2016 Financial Results"
08/08/2016 8-K Form 8-K - Current report
05/09/2016 8-K Quarterly results
Docs: "Horizon Pharma plc Announces First-Quarter 2016 Financial Results"
02/29/2016 8-K Form 8-K - Current report
11/06/2015 8-K Quarterly results
Docs: "Horizon Pharma plc Announces Exceptional Third-Quarter 2015 Financial Results and Significantly Raises Full-Year 2015 Sales and Adjusted EBITDA Guidance"
08/07/2015 8-K Quarterly results
Docs: "Horizon Pharma plc Announces Record Second Quarter 2015 Financial Results"
05/08/2015 8-K Quarterly results
Docs: "Horizon Pharma plc Announces First Quarter 2015 Financial Results and Increases 2015 Guidance"
02/27/2015 8-K Quarterly results
Docs: "Horizon Pharma plc Announces Fourth Quarter and Full Year 2014 Financial Results and Raises Guidance for 2015"
11/06/2014 8-K Quarterly results
Docs: "Horizon Pharma plc Reports Third Quarter 2014 Financial Results and Raises Guidance for 2014 and 2015"
08/07/2014 8-K Quarterly results
Docs: "Horizon Pharma Reports Second Quarter 2014 Financial Results and Provides Business Update"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy